- ReForm appoints four new Directors preparing the company for significant growth -
WOBURN, Mass., September 21, 2021--(BUSINESS WIRE)--ReForm Biologics, Inc., a company developing a new generation of innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of four new Directors with significant life science and biotechnology experience: Roopom Banerjee, Kirsten Flowers, Stuart Randle and Edward Sullivan.
"A Board of Directors should reflect a company's mission, vision, and stage of development. These four new board members will deepen ReForm Biologic's commercial, strategic, financial, and medical expertise while expanding the board to be more diverse and inclusive for our next stage of growth," said Jim Sherblom, Executive Chairman, ReForm Biologics, Inc. "We look forward to working with Roopom Banerjee, Kirsten Flowers, Stuart Randle and Edward Sullivan as we continue to advance our pipeline of gentler medicines to address the needs of vulnerable patients. This is a crucial time in the evolution of ReForm and we are grateful to be able to benefit from the experience and insights of these new Directors."
Roopom Banerjee has over 25 years of experience in corporate strategy, investment banking, private equity, company formation and operating leadership. Roopom is currently the Managing Partner of WhiteLeaf Advisors, a Strategic Advisor to Bain Capital, and an Operating Partner at CRG Investments. Previously he was President and CEO of Raindance Technologies which pioneered the first liquid biopsy blood tests for noninvasive cancer detection, as well as a Director of Investment Banking at Leerink Swann, and a consultant at McKinsey. Roopom holds dual BS degrees in Biology and Economics from MIT, and an MPP from Harvard.
Kirsten Flowers brings more than 15 years of pharmaceutical and biotech experience and is currently the Chief Commercial Officer for Kura Oncology. She has previously served as SVP of Commercial Operations at Array Biopharma where she built and led the commercial organization that delivered the successful launch of Braftovi® + Mektovi® for patients with BRAF-mutant melanoma. Before joining Array, Kirsten held several leadership positions within Pfizer including the U.S. commercial lead for the launch of the blockbuster drugs IBRANCE® in breast cancer and INLYTA® in renal cell carcinoma. Kirsten earned her MBA from Harvard Business School, and her BS in Molecular & Cellular Biology and Psychology from the University of Arizona.
Stuart Randle has 30 years of biomedical experience including as Division President of Baxter Healthcare, President and CEO of ACT Medical, President and CEO of GI Dynamics, and most recently, President and CEO of Ivenix. He serves on the Board of Directors of Teleflex (TFX) and Beacon Roofing Supply (BECN) and was previously on the Boards of Flex Pharma (FLKS), Specialized Health Products International (SHPI), and GI Dynamics (GID). He was also an Entrepreneur-in-Residence for Advanced Technology Ventures, a healthcare and IT venture capital firm. Stuart holds a BS from Cornell and a Northwestern MBA.
Edward is a comprehensive business strategist and financial expert with 35 years of experience advising public and private companies at all stages of development from early stage, pre-IPO businesses to multi-billion-dollar market cap public companies. Trusted counselor to multinational corporations in various industries adept at guiding businesses through years of growth and transformational change. Valued by boards, clients, and colleagues for honest feedback, a steadfast character, and collaborative leadership style. Edward holds a BS in Accounting from Bryant University.
About ReForm Biologics, Inc.
ReForm Biologics’ mission is to develop improved biologic formulations derived from our proprietary, patented technology platform to enhance patients’ lives, particularly for fragile populations such as children and the elderly. We are doing this by improving the viscosity and stability of known biologics, with our own formulations as well as for those of other biopharmaceutical companies to make their medicines gentler for patients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005203/en/
Shoreline Biotech Communications